Special Issue "Topoisomerases as Targets for Novel Drug Discovery"
Deadline for manuscript submissions: 31 March 2024 | Viewed by 10765
A diverse family of efficient biological nanomachines, DNA topoisomerases monitor vital cellular processes such as replication and transcription. Because of their ability to efficiently modulate the topological changes of the DNA molecule, they are often referred to as the “magicians of the DNA world”. They are found in all prokaryotic and eukaryotic cells and even in some viruses and are involved in several processes that affect the DNA molecule. They are broadly classified as type I and type II topoisomerase and operate via complex catalytic cycles that allow DNA strands or duplexes to pass each other.
Molecules targeting DNA topoisomerases are well-established drugs that are widely used in therapy, either as antibacterial agents to treat numerous infections or in oncology as chemotherapeutic agents. However, current clinically used drugs targeting DNA topoisomerases face numerous challenges and limitations, such as the rapid emergence of bacterial resistance and the serious side effects of topoisomerase chemotherapeutics. Therefore, intensive research is currently underway to expand the understanding of these intriguing enzymes that modulate DNA topology and to develop new molecules that could overcome these challenges and lead to a new generation of drugs targeting topoisomerases.
In this special issue, Pharmaceuticals invites authors to submit research and review articles discussing new insights, perspectives, and challenges related to the study of topoisomerases and their use as drug targets. Topics may include a broad range of research, such as the study of bacterial or human topoisomerases by experimental or in silico methods, and the design, synthesis, and experimental characterization of new molecules targeting all members of the DNA topoisomerase family. The collection of manuscripts will be published as a Special Issue of the journal.
Prof. Dr. Andrej Perdih
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- type I topoisomerase
- type II topoisomerase
- DNA Gyrase
- DNA topology
- catalytic inhibitors
- topo II poisons
- DNA gyrase inhibitors
- Novel bacterial topoisomerase inhibitors (NBTI)
- anticancer agents
- antibacterial agents